Latest from Sue Sutter
President Trump’s 10% tariff on active pharmaceutical ingredients and finished dosage forms could push some generic drug makers to exit therapeutic categories if they cannot absorb the new costs, which could lead to shortages.
The sudden halt to grants and health agency communications is causing stress for the rare disease advocacy community, speakers said at a recent rare disease symposium.
Pink Sheet reporter and editors discuss what pushed a crucial Senate Finance Committee swing vote to support Robert F. Kennedy Jr. as HHS Secretary and the FDA slowly expanding its communications with the public amid the Trump Administration freeze.
There has been “a lot of fear and anxiety” resulting from the Trump Administration’s early actions aimed at freezing grants and FDA communications, NORD’s Pamela Gavin says.
As the US FDA determines what media inquiries it can respond to, HHS is deciding whether planned actions or meetings can move forward, depending on whether they are deemed mission-critical.
The FDA announcement of the novel, non-opioid drug’s approval highlights public health implications, which probably helped it clear the communications freeze. Recent website updates and forthcoming Federal Register notices suggest the freeze could be thawing slowly.